Several ROR1-targeting modalities, including monoclonal antibodies (e.g., zilovertamab), antibody–drug conjugates (e.g., zilovertamab-vedotin), and chimeric antigen receptor T-cell (CAR-T) therapies, have demonstrated potent anti-tumor efficacy in preclinical and clinical studies. This evidence concerns the gene ROR1 and neoplasm.